Redwood City, Calif., Dec. 10, 2015 /PRNewswire/ - Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the Centers for Medicare & Medicaid Services (CMS) have approved a transitional pass-through payment for High Frequency Stimulation under the Medicare hospital outpatient prospective payment system effective beginning January 1, 2016. This pass-through payment for HF10™ therapy will be in addition to the established reimbursement for spinal cord stimulation devices. CMS determined the Senza SCS System delivering HF10 therapy met the criteria for a new device category based on the published randomized control trial (RCT) evidence submitted. The Healthcare Common Procedure Coding System (HCPCS) code for this new device category is C1822. Specific coding and payment information regarding this new pass-through device category will be published in January 2016 and will be accessible on the CMS website at http://www.cms.hhs.gov/Transmittals.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
Nevro Investor Relations
SOURCE Nevro Corp.